Dongfang Liu sold $251k of NUVB
CHIEF MEDICAL OFFICER at Nuvation Bio Inc.. 50,000 shares at an average of $5.02, traded Apr 17, 2026, filed Apr 21, 2026.
Score components
- +15RoleOfficer
- +13Trade size$251k at market
- +20Share of holdings soldSold 74% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -6.3%, 3m +25.8%, 6m -.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001937915-26-000004, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Apr 17, 2026 | MOption exercise Class A Common Stock10b5-1 | +50,000 | $1.94 | $97k | 68,000 | Apr 21, 2026 |
| Apr 17, 2026 | SOpen-market sale Class A Common Stock10b5-1 | -50,000 | $5.02 | $251k | 18,000 | Apr 21, 2026 |
| Apr 17, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -50,000 | $0.00 | $0 | 430,000 | Apr 21, 2026 |
Related signals
Other insiders at Nuvation Bio Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 21Weak | Nuvation Bio Inc. | Gary Hattersley CHIEF SCIENTIFIC OFFICER | $709k 100,000 shares | -100% | |
| 37Weak | Nuvation Bio Inc. | Stacy Markel CHIEF PEOPLE OFFICER | $753k 125,000 shares | -79% | |
| 31Weak | Nuvation Bio Inc. | Kerry Wentworth CHIEF REGULATORY OFFICER | $379k 63,000 shares | -54% | |
| 36Weak | Nuvation Bio Inc. | Philippe Sauvage Chief Financial Officer | $286k 47,668 shares | -79% | |
| 36Weak | NUVBbuy Nuvation Bio Inc. | Robert Mashal director | $118k 25,000 shares | +13% | |
| 10Weak | Nuvation Bio Inc. | Kerry Wentworth CHIEF REGULATORY OFFICER | $184k 36,750 shares | -41% | |
| 32Weak | Nuvation Bio Inc. | Kerry Wentworth CHIEF REGULATORY OFFICER | $904k 200,000 shares | -79% | |
| 60Notable | Nuvation Bio Inc. | Dongfang Liu CHIEF MEDICAL OFFICER | $1.2M 150,000 shares | -89% | |
| 46Moderate | Nuvation Bio Inc. | Dongfang Liu CHIEF MEDICAL OFFICER | $155k 20,000 shares | -71% | |
| 60Notable | Nuvation Bio Inc. | Gary Hattersley CHIEF SCIENTIFIC OFFICER | $2.7M 369,051 shares | -534% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.